PROK ProKidney Corp.
Company Analysis
Latest News
🔴 ProKidney is trading 5.3% down today amid broader risk-off market pressure
ProKidney is trading at $1.89, down -5.28%, on September 9, 2026, amid softer U.S. markets, rising oil prices, geopolitical tensions, and renewed interest-rate...
🟢 ProKidney is trading 5.47% up today with no clear company-specific catalyst
ProKidney is trading 5.47% up now at $2.02, with no September 4, 2026 company-specific announcement or reliable report directly explaining the move. - The...
🟢 ProKidney rises 5.4% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
ProKidney Director Sells Entire $1.07 Million Stake
ProKidney Corp. director Brian JG Pereira sold his entire holding of 757,164 Class A Common Stock shares. The transactions occurred between August 18 and...
🟢 ProKidney is trading 11.62% up today as biotech sector rallies
ProKidney is trading 11.62% up now at $1.58, likely reflecting biotech-sector strength rather than a company-specific announcement. - No clear...
🟢 ProKidney is trading 7.39% up today; catalyst remains unclear
ProKidney is trading 7.39% up at $1.52, with no clearly identified company-specific catalyst for the August 21, 2026 move. - Director Brian JG Pereira sold...
🔴 ProKidney falls 5.7% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 ProKidney rises 5.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 ProKidney is trading 5.64% up today — apparently a trading rebound
ProKidney is trading 5.64% up now at $1.41, apparently in a trading rebound without a clearly identified company-specific catalyst. - Shares fell 5.34% on...
ProKidney achieves pivotal Phase 3 enrollment milestone during second quarter 2026
ProKidney reached a significant clinical milestone in the second quarter of 2026 by completing enrollment for its Phase 3 PROACT 1 accelerated approval...
🔴 ProKidney is trading 6.41% down today after a quarterly loss and revenue miss
ProKidney is trading 6.41% down now at $1.31 after reporting a $0.15 quarterly loss versus the $0.13 consensus estimate and $0.15 million in revenue, missing...
ProKidney Hits Phase 3 Enrollment Milestone as R&D Spending Widens Loss
ProKidney Corp. completed patient enrollment for the Phase 3 PROACT 1 efficacy analysis of its cell therapy, rilparencel. This pivotal trial evaluates the...